Application of Rap2b amino acid site as target for preparing medicine for treating colorectal cancer

By intervening in the palmitoylation modification of Rap2b, the small-molecular compound PTG-101 blocks the Rap2b amino acid site, solving the problem of colorectal cancer cell migration and invasion, providing a new targeted treatment plan, significantly improving the treatment of colorectal cancer Effect.

CN118987219APending Publication Date: 2024-11-22XINXIANG MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411091361.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The high incidence and high mortality rate of colorectal cancer bring serious human and economic burdens to society and families. The existing treatment methods are limited, especially in patients with metastatic colorectal cancer. There are problems with drug resistance and recurrence, and there is a lack of effective Targeted therapy options.

Method used

By interfering with Rap2b and its function, using cysteines at positions 176 and 177 of Rap2b amino acid sites for palmitoylation modification blocking, the small molecule compound PTG-101 is designed to specifically block or mutate these sites, and regulate Palmitoylation modification of Rap2b protein, thereby inhibiting the migration and invasion of colorectal cancer cells.

Benefits of technology

It effectively inhibits the palmitoylation modification of Rap2b, reduces the migration and invasion ability of colorectal cancer cells, and provides new target points to develop methods for the treatment of colorectal cancer, which significantly improves the survival and disease control of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987219A_ABST
    Figure CN118987219A_ABST
Patent Text Reader

Abstract

The invention provides application of a Rap2b amino acid site as a target for preparing a medicine for treating colorectal cancer, and belongs to the technical field of gene medicines. According to the application of the Rap2b amino acid site serving as the target for preparing the medicine for treating the colorectal cancer, the Rap2b amino acid site is cysteine at the 176th site and / or 177th site on a Rap2b amino acid sequence, and the Rap2b amino acid sequence is shown as SEQ ID NO: 1. The invention provides a novel application of a colorectal treatment target, and also provides a design strategy and a use method of a small molecule compound required by the application, so that an effective method for treating colorectal cancer and a method for preparing a treatment medicament can be developed on the basis of the design strategy and the use method.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of gene medicine, and in particular to an application of a Rap2b amino acid site as a target for preparing a drug for treating colorectal cancer. Background Art

[0002] Colorectal cancer is a cancer that accumulates in the colon and / or rectum. Its incidence rate increases with age. It ranks third in the incidence of cancer in the world, accounting for about 10% of all cancer cases, and eventually leads to serious injuries and death. As a highly prevalent malignant tumor, about 30% of colorectal cancer patients have already developed distant metastasis when diagnosed, and up to 30% of patients die from tumor metastasis and recurrence. The high incidence and high mortality rate of colorectal cancer have brought serious humanistic and economic burdens to society and families. Clinically, the treatment principle of colorectal cancer is comprehensive treatment with surgery as the main method and radiotherapy and chemotherapy as the auxiliary methods. In recent years, with the in-depth research on genotyping and targeted therapy, molecular targeted drugs have become the first-line solution for personalized treatment and comprehensive treatment, providing better survival benefits for patients with colorectal cancer, especially metastatic colorectal cancer. Therefore, the discovery of new therapeutic targets for colorectal cancer is of great significance for the development of safe and effective treatment methods and the preparation of therapeutic agents.

[0003] Rap2b is a member of the Rap subfamily of the small G protein / Ras superfamily. It was first discovered in human platelets and was subsequently confirmed to be a possible oncogene that promotes proliferation, migration, and invasion in a variety of malignant tumors. Many studies have shown that Rap2b is abnormally expressed in colorectal cancer, especially specifically elevated in combined lymph node metastasis, increasing drug resistance and recurrence rates of colorectal cancer. Therefore, it is believed that Rap2b is involved in colorectal cancer metastasis, promotes the development of colorectal cancer, and is a negative regulatory factor in colorectal cancer. Therefore, intervening in Rap2b and its function is a potential strategy for treating colorectal cancer. Summary of the invention

[0004] The purpose of the present invention is to provide intervention Rap2b and its function, and develop drugs for treating colorectal cancer.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides an application of a Rap2b amino acid site as a target for preparing a drug for treating colorectal cancer. The Rap2b amino acid site is the 176th and / or 177th cysteine ​​on the Rap2b amino acid sequence. The Rap2b amino acid sequence is shown in SEQ ID NO: 1.

[0007] Preferably, the drug is prepared for treating colorectal cancer by blocking the post-translational modification of cysteine ​​at position 176 and / or 177 on the amino acid sequence of Rap2b.

[0008] Preferably, the post-translational modification refers to palmitoylation modification.

[0009] The present invention also provides a motif for blocking palmitoylation modification after translation of Rap2b amino acid sites, wherein the motif is a naturally derived sequence targeting the NH-GCCS-CO motif or a naturally derived sequence targeting the NH-EGSSSA-CO motif.

[0010] Preferably, the naturally derived sequence targeting the NH-EGSSSA-CO motif is NH-ESFEPLSINTTE-CO.

[0011] Preferably, the NH-EGSSSA-CO motif interacts with the NH-ESFEPLSINTTE-CO motif to form a β-folded structure.

[0012] Preferably, the simplified sequence of the NH-ESFEPLSINTTE-CO motif is H2N-ESFEXTE-COOH, wherein X represents 1 to 6 arbitrary amino acids.

[0013] Preferably, X is β-alanine, resulting in the motif H2N-ESFEβATE-COOH.

[0014] Preferably, the H2N-ESFEβATE-COOH motif simulates the conformation of the NH-ESFEPLSINTTE-CO motif, interacts with the NH-EGSSSA-CO motif through hydrogen bonds, and is used to treat colorectal cancer.

[0015] The present invention also provides an application of the motif in preparing a drug for treating colorectal cancer.

[0016] The present invention specifically blocks the 176th and 177th cysteines on the amino terminal sequence of Rap2b or mutates them into sulfhydryl-free amino acids through small molecule compounds, thereby blocking or reducing the palmitoylation modification of Rap2b protein, thereby directly regulating the migration and invasion of colorectal cancer cells by regulating the palmitoylation modification of cysteines at positions 176 and 177. Cysteines at positions 176 and 177 of Rap2b are located at the carboxyl end of the protein. By designing small molecule compounds with high binding affinity, the binding of cysteines at positions 176 and 177 to palmitic acid is blocked, and PTG (Palmitoylation-targeting-peptide) is named after this. By screening HCT116 and HCT8 cells, it was found that 50 μM PTG-101 had an inhibitory effect on Rap2b palmitoylation modification that was basically consistent with ABHD17a overexpression. At the same time, through the colon cancer xenograft mouse model, it was verified in vivo that Rap2b overexpression promotes lung metastasis of colon cancer, while PTG-101 and mutations of cysteine ​​at positions 176 and 177 of Rap2b can inhibit this promotion. In addition, ABHD17a is an acyl protein thioesterase of Rap2b, which can remove the palmitoylation modification of Rap2b. The present invention confirms that ABHD17a overexpression leads to a significant decrease in the palmitoylation modification level of Rap2b in two colon cancer cells, HCT116 and HCT8, thereby inhibiting cell migration and invasion. The present invention provides the application of a new colorectal therapeutic target, and also provides a small molecule compound design strategy and use method required for the application. Based on this, an effective method for treating colorectal cancer and a method for preparing a therapeutic agent can be developed. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 The expression of Rap2b protein in colorectal cancer tissues was observed by western blotting.

[0018] Figure 2 The expression of Rap2b protein in colon cancer tissues observed by immunohistochemical staining.

[0019] Figure 3 This is a Kaplan-Meier analysis of the correlation between Rap2b expression and disease-free survival in 101 patients with colon cancer.

[0020] Figure 4 The palmitoylation modification of endogenous (not transfected with Flag-Rap2b plasmid) and exogenous Rap2b (transfected with Flag-Rap2b plasmid) in HCT116 cells was detected by Acyl-RAC.

[0021] Figure 5The palmitoylation modification of HCT116 cells transfected with Rap2b, Rap2b-C176S, Rap2b-C177S and Rap2b-C176S / C177S was detected by Acyl-RAC.

[0022] Figure 6 The effect of HCT116 cells transfected with APT1, APT2, PPT1, PPT2 and ABHD17a plasmids on Rap2b palmitoylation modification detected by Acyl-RAC.

[0023] Figure 7 This is the process of knocking out endogenous Rap2b in HCT116 cells using CRISPR-CAS9 technology and the sequencing and identification results.

[0024] Figure 8 To observe the subcellular localization and plasma membrane distribution of Rap2b in HCT116 cells before and after the palmitoylation modification site mutation through IF and cell membrane protein extraction experiments.

[0025] Fig. 9 To observe the effect of ABHD17a-Flag overexpression on the subcellular localization and plasma membrane distribution of Flag-Rap2b in HCT116 Rap2b KO cells through IF and cell membrane protein extraction experiments.

[0026] Fig.10 The cell scratch experiment was used to observe the effect of palmitoylation modification site mutation on Rap2b migration ability in Rap2b KO cells.

[0027] Fig.11 A cell scratch assay was performed to observe the effect of Rap2b on cell migration ability in Rap2b KO cells under the intervention of ABHD17a overexpression.

[0028] Fig.12 Transwell and Matrigel experiments were used to observe the effect of Rap2b on cell invasion ability under the intervention of ABHD17a overexpression.

[0029] Fig.13 The Acyl-RAC experiment was used to observe the changes in Rap2b palmitoylation modification under the intervention of EGF and Wortmannin.

[0030] Fig.14 The subcellular distribution of Rap2b under Wortmannin intervention conditions was observed by extracting cell membrane proteins.

[0031] Fig.15In order to observe the regulation of Rap2b on cell migration under the condition of Wortmannin intervention through cell scratch experiment.

[0032] Fig.16 Transwell and Matrigel experiments were used to observe the regulation of Rap2b on cell migration and invasion under Wortmannin intervention conditions.

[0033] Fig.17 To observe the changes in phosphorylation modification of AKT / GSK 3β, the downstream effector protein of PI3K signaling pathway under EGF intervention conditions through WB experiment.

[0034] Fig.18 Design and docking prediction of PTG-101. (A) Molecular dynamics simulation of H2N-ESFEβATE-COOH (PTG-101, green) conformation, similar to NH-ESFEPLSINTTE-CO (blue). (B) Molecular dynamics simulation predicted docking mode of PTG-101 (green) with NH-EGSSSA-CO motif (amino acids 469-474) in the crystal structure of isoglucanase. Hydrogen bonds are indicated by blue dashed lines.

[0035] Fig.19 The Acyl-RAC experiment was used to observe the changes in Rap2b palmitoylation modification under the intervention of different doses of PTG-101.

[0036] Fig. 20 The subcellular distribution of Rap2b under PTG-101 intervention conditions was observed through IF and cell membrane protein extraction experiments.

[0037] Fig.21 A cell scratch experiment was used to observe the regulation of Rap2b on cell migration under PTG-101 intervention conditions.

[0038] Fig. 22 Transwell and Matrigel experiments were used to observe the regulation of Rap2b on cell migration and invasion under PTG-101 intervention conditions.

[0039] Fig.23 To investigate the regulatory effect of PTG-101 on Rap2b-mediated tumor metastasis in a colon cancer xenograft mouse model.

[0040] Fig.24 To observe the regulation of PTG-101 on the lesion severity of colon cancer xenograft mouse model through lung HE staining, body weight and survival changes.

[0041] Fig.25To observe the regulatory effect of PTG-101 on the AKT / GSK 3β signaling pathway in a colon cancer xenograft mouse model by WB. DETAILED DESCRIPTION

[0042] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0043] Example 1

[0044] Before describing the embodiments of the present invention, clinical specimens and case data of patients with colon cancer were first collected to evaluate the changes in the expression of Rap2b at the protein level and its correlation with the disease-free survival of the patients.

[0045] 1. Collection of clinical samples and case data: A total of 117 patients with colon cancer who were to undergo surgery were from the First Affiliated Hospital of Xinxiang Medical College, China. Colorectal cancer tissues and corresponding adjacent cancer tissues were collected. All patients did not receive adjuvant chemotherapy or radiotherapy before surgery. Clinical samples were subjected to immunohistochemistry (IHC) staining in the Department of Pathology of the First Affiliated Hospital of Xinxiang Medical College. At the same time, some samples were frozen in liquid nitrogen for WB experiments. This study was approved by the Ethics Committee of Xinxiang Medical College.

[0046] Among them, the steps of paraffin section and immunohistochemical staining are as follows:

[0047] Paraffin section: After fixing the sample with 10% formaldehyde for 48 hours, dehydrate it with graded ethanol (50%, 75%, 80%, 90%, 95%, 100%) and place it in each level of ethanol for 2 hours. Soak it in anhydrous ethanol / xylene mixture (1:1) for 20 minutes, and make xylene transparent for 20 minutes. If the dehydration is complete, you can observe that the sample is transparent. Soak the sample in soft wax for 3 hours and hard wax for 2 hours, embed the tissue in 50℃ paraffin, and start sectioning after it is fully cooled and solidified.

[0048] IHC staining: paraffin sections were heated at 60℃ for 2h, and then dewaxed and hydrated in order of xylene (10min) → xylene (10min) → anhydrous ethanol (5min×2) → 95% ethanol (5min×2) → 90% ethanol (5min) → 85% ethanol (5min) → 80% ethanol (5min) → 75% ethanol (5min). Endogenous peroxidase was blocked with 3% H2O2, and the sections were incubated at room temperature and away from light for 30min. Antigens were repaired by heating with citric acid repair solution, and the sections were kept at boiling state for a total of 20min. After PBS rinsing, 10% goat serum was used to block the sections at room temperature for 2h, and an appropriate amount of Rap2b antibody dilution solution was added, and the sections were incubated at 4℃ overnight. Then, rabbit antibody dilution solution was added, and the sections were incubated at room temperature for 1h. After PBS rinsing, DAB staining solution was added, and the sections were incubated at room temperature for 0.5h. The nuclei were counterstained with hematoxylin staining solution, and the sections were incubated at room temperature for 1min. Dehydrate with gradient alcohol from 80% ethanol (2 min) → 95% ethanol (2 min) → 100% ethanol (2 min×2), transparentize with xylene (5 min×2), and seal with neutral gum.

[0049] The steps for western blotting are as follows:

[0050] WB sample preparation: After the clinical sample was ground with liquid nitrogen, 1 ml of RIPA lysis buffer (P0013B, Beyotime) containing 1×PI (protein inhibitor) was added to every 35 mg, and after sufficient lysis, the sample was centrifuged at 12000 rpm and 4°C for 10 min, and the supernatant was collected. After the protein concentration was detected by BCA (Bicinchoninic acid) method, a 1μg / μl sample was prepared, and an equal volume of 2×SDS-PAGE Loading buffer was added, and the sample was heated at 100°C for 10 min to denature the sample.

[0051] SDS-PAGE (SDS-polyacrylamide gel electrophoresis): Prepare 12% separation gel and 5% concentration gel, add appropriate amount of sample to the sample well, separate the groups with protein markers, and add appropriate amount of 1×SDS-PAGE electrophoresis solution to the electrophoresis tank. Setting: The initial voltage is 80V, and it is increased to 135V after the sample enters the separation gel. Observe the corresponding position of the target protein through the marker, and stop the electrophoresis at the appropriate time or when bromophenol blue migrates to the bottom of the gel.

[0052] Transfer: Place the sponge pad, filter paper, SDS-PAGE gel, PVDF membrane pretreated with methanol, filter paper, and sponge pad in the transfer sandwich from the negative electrode (black board) to the positive electrode (transparent board) in order to avoid bubbles and insert the transfer tank correctly according to the direction of the electrode. To avoid excessive heat generation, place an ice box in the transfer tank and add pre-cooled 1× SDS-PAGE transfer buffer. Settings: The current is 300mA, and the transfer time is set according to the molecular weight of the protein, usually 90min.

[0053] Antibody incubation and image acquisition: After the transfer, the pre-stained marker band can be observed on the PVDF membrane. Rinse with TBST, put in 5% skim milk, and block at room temperature for 1 hour. Cut the PVDF membrane according to the experimental purpose, put in the Rap2b antibody (ab101369, Abcam) dilution solution, incubate at 4°C overnight, then put in the rabbit antibody dilution solution (AS014, Abclonal), and incubate at room temperature for 1 hour. Rinse thoroughly with TBST 3 times, evenly add exposure solution to the PVDF membrane, put it in the darkroom of the luminescence imager for exposure, and collect images.

[0054] Figure 1 The expression of Rap2b protein in colorectal cancer tissues was observed by western blotting. Figure 1 Normal refers to normal colon tissue adjacent to the cancer, and CRC refers to colorectal cancer tissue. The results showed that the expression of Rap2b in colorectal cancer tissue was significantly higher than that in adjacent to the cancer tissue.

[0055] Figure 2 The expression of Rap2b protein in colon cancer tissues observed by immunohistochemical staining. Figure 2 Normal colon refers to normal colon tissue adjacent to the cancer, Primary CRC refers to primary colon cancer, and Metastatic CRC refers to metastatic colon cancer. The results showed that the expression of Rap2b was abnormally increased in colon cancer, especially metastatic colon cancer.

[0056] 2. Correlation analysis between clinical parameters and Rap2b protein expression: Based on the collected case data, the correlation analysis between age, gender, TNM, lymph node metastasis, distant metastasis, Ras mutation and microsatellite stability and Rap2b protein expression was performed by immunohistochemical staining. The experimental results showed (Table 1, Figure 3 ), Rap2b protein expression increased, the disease-free survival of colorectal cancer patients decreased, and high Rap2b expression was positively correlated with lymph node metastasis and distant metastasis of colon cancer.

[0057] Table 1. Correlation between clinical parameters and Rap2B protein expression in colorectal cancer patients (n=117).

[0058]

[0059]

[0060] The above is an evaluation of the changes in the expression level of Rap2b protein in patients with colorectal cancer and its correlation with the disease-free survival of patients. The results show that the expression of Rap2b in colorectal cancer tissues is significantly higher than that in adjacent tissues, especially in metastatic colon cancer, and the expression of Rap2b is negatively correlated with disease-free survival, and positively correlated with lymph node metastasis and distant metastasis of colon cancer.

[0061] Example 2

[0062] This example attempts to explore the molecular function of palmitoylation modification of Rab2b and its possible regulatory mechanism, and further verify the regulation of Rab2b function by palmitoylation modification of cysteine ​​at positions 176 and 177 of Rab2b. The amino acid sequence of Rap2b is as follows (SEQ ID NO: 1), the two underlined “ CC ” refers to cysteine ​​176 and 177 of Rab2b;

[0063] MREYKVVVLGSGGVGKSALTVQFVTGSFIEKYDPTIEDFYRKEIEVDSSPSVLEILDTAGTEQFASMRDLYIKNGQGFILVYSLVNQQSFQDIKPMRDQIIRVKRYERVPMILVGNKVDLEGEREVSYGEGKALAEEWSCPFMETSAKNKASVDELFAEIVRQMNYAAQPNGDEG CC SACVIL

[0064] This example was mainly performed in two colon cancer cells, HCT116 and HCT8. However, since the results of the two are similar, only the experimental results of HCT116 are provided below.

[0065] (I) Identification of palmitoylation modification of Rap2b and screening of acyl protein thioesterases

[0066] 1. Cell Culture and Transfection

[0067] Cell culture: HCT116 cells (TcHu133) were purchased from the Cell Bank of the Chinese Academy of Sciences and cultured in DMEM / high glucose medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin solution in a 5% CO2 incubator at 37°C.

[0068] Cell transfection: HCT116 cells using Lipofectamine TM 3000 reagent and reduced serum medium OPTI-MEM were used for transfection, and the transfection time was generally 24h.

[0069] 2. Obtaining the expression vector

[0070] According to experimental requirements, expression vectors expressing human Flag-Rap2b (NM_002886.4), Flag-Rap2b-C176S, Flag-Rap2b-C177S, Flag-Rap2b-C176S / C177S-Flag; APT1-HA (NM_008866.2), APT2-HA (NM_011942.1), PPT1-HA (NM_008917.3), PPT2-HA (NM_001302395.1), and ABHD17a-HA (NM_145421.2) were obtained (HA is a tag peptide).

[0071] Among them, the expression vectors of human Rap2b (NM_002886.4), APT1-HA (NM_006330.3), APT2-HA (NM_007260.3), PPT1-HA (NM_000310.4), PPT2-HA (NM_005155.6), and ABHD17a-HA (NM_031213.3) were purchased from Beijing Sino Biological Co., Ltd.; Rap2b-C176S, Rap2b-C177S, and Rap2b-C176S / C177S were obtained using the Fast Mutagenesis System using Flag-Rap2b as a template, and sequence analysis and verification were performed by sequencing.

[0072] APT1, APT2, PPT1, PPT2 and ABHD17a, as acyl-protein thioesterases (APTs), have the function of removing palmitoylation modification. The APTs expression vector constructed in this example is used to remove the palmitoylation modification of Rap2b.

[0073] 3.Acyl-RAC (Acyl Resin Assisted Capture)

[0074] Cell culture was performed in 10 cm cell culture dishes. When the density of HCT116 cells reached 50% to 60%, the cells were transfected with Lipofectamine TM3000 indicates that the corresponding plasmid was used for transfection. 24h after cell transfection, the cells were rinsed with PBS, the attached cells were separated by scraper, centrifuged at 4℃ for 5min, 500rcf, and the cells were collected. Each 10cm dish cell was fully lysed with 1ml of lysis buffer (P0013, Beyotime) containing 1×PI, centrifuged at 4℃ for 10min, 12000rpm, and the supernatant was collected. The quality of total protein in the supernatant was detected by BCA method. Then 2mg of protein was added, 4 times the volume of pre-cooled acetone, placed at -20℃ for 30min, centrifuged at 4℃ for 10min, 12000rpm, and the protein was precipitated. 1ml Blocking buffer (100mM HEPES, 1mM EDTA, 2.5% SDS, 50mM NEM pH7.5, 1×PI) was added to the protein precipitate to dissolve and block the protein, and incubated at 50℃ for 1h. The protein was precipitated with pre-cooled acetone and washed with 70% acetone for 4 times, and then dissolved with 650 μl Binding buffer (100 mM HEPES, 1 mM EDTA, 1% SDS).

[0075] Take 50 μl of sample as the "input" group for comparing proteins between groups.

[0076] The remaining samples were equally divided into two groups. One group was added with 40 μl 2M HA (hydroxylamine) pH 7.0, hereinafter referred to as the "+HA" group or "HA+" group; the other group was not treated with HA and was replaced with 40 μl 2M NaCl, hereinafter referred to as the "-HA" group or "HA-" group, serving as a control for the +HA group.

[0077] Then, 50 μl of pretreated thiopropyl Sepharose 6B was added to each of the two groups, and the mixture was rotated and incubated at room temperature for 4 h to enrich the palmitoylated proteins. Then, 1 ml of Binding buffer was added to wash the beads 5 times, and non-specific binding proteins were eluted. The beads were centrifuged at 4 °C for 1 min, 2500 rpm. Then, 40 μl of Laemmli buffer (2.1% SDS, 66 mM Tris-HCl pH 7.4, 26% glycerol, 50 mM DTT) was added, and the palmitoylated proteins were eluted. The beads were centrifuged at room temperature for 2 min, 2500 rpm, and the supernatant was collected. An equal volume of 2× SDS-PAGE Loading buffer was added, and the samples were prepared and analyzed according to WB, as shown in the following figure. Figures 4 to 6 shown.

[0078] Figure 4 The palmitoylation modification of endogenous (not transfected with Flag-Rap2b plasmid, right) and exogenous Rap2b (transfected with Flag-Rap2b plasmid, left) in HCT116 cells detected by Acyl-RAC. Figure 4It can be seen that palmitoylated Rap2b protein can be observed in the +HA group (regardless of whether the Flag-Rap2b plasmid is transfected), while there is no protein in the -HA group.

[0079] The Acyl-RAC assay is based on the specific binding of palmitoyl groups to Cys residues through sulfhydryl bonds. The amino acid sequence of a protein may contain multiple Cys residues. Assuming that some or all of the Cys residues are palmitoylated, the first step is to block the free Cys residues by N-ethylmaleimide (NEM). In the second step, HA breaks the sulfhydryl bonds and reduces the Cys residues bound to the palmitoyl groups. In the third step, thiol-containing agarose binds to the reduced Cys residues through disulfide bonds. In the fourth step, the protein is eluted and identified by immunoblotting and specific antibodies. Therefore, Figure 4 The experimental results indicate that Rap2b is a palmitoylated protein.

[0080] Figure 5 The results show that in the HA+ group, the palmitoylation level of Rap2b mutants decreased to varying degrees, especially Rap2b-C176S / C177S (2CS), which showed that the palmitoylation level of Rap2b mutants decreased most significantly, indicating that the 176th and 177th cysteines of Rap2b are palmitoylation sites of proteins.

[0081] Figure 6 The effect of HCT116 cells (transfected with Rap2b plasmid) transfected with APT1, APT2, PPT1, PPT2 and ABHD17a plasmids on Rap2b palmitoylation detected by Acyl-RAC. The experimental results showed that in the HA+ group, ABHD17 overexpression significantly inhibited Rap2b palmitoylation, suggesting that ABHD17a is an acyl protein thioesterase that regulates Rap2b palmitoylation.

[0082] (II) Study on the function and regulatory mechanism of Rap2b palmitoylation modification

[0083] This group of studies mainly includes observing the effect of Rap2b palmitoylation modification on protein subcellular localization and its regulatory effect on Rap2b-mediated tumor cell migration and invasion.

[0084] 1. Construction of HCT116 Rap2b KO cell line

[0085] In order to exclude the influence of endogenous Rap2b on the experimental results, Rap2b was knocked out in HCT116 cells by CRISPR-CAS9 gene editing technology to construct Rap2b KO cells. A pair of guide RNA (gRNA) was designed using an online tool (http: / / crispor.tefor.net / ) to target the destruction of the exon of the human Rap2b genome (Gene ID: ENST00000323534.4). The double-stranded oligonucleotide of gRNA was synthesized by Bioligo and cloned into the pX458 vector (48138, Addgene). The two expression vectors were expressed by Lipofectamine TM 3000 were co-transfected into HCT116 cells, and the transfection results were observed by fluorescence microscopy after 24 hours, and further fluorescence sorting was performed by flow cytometry. After single cell amplification, genotyping was performed at the DNA level by sequencing and PCR, and the expression of Rap2b at the protein level was detected by WB.

[0086] Figure 7 The process of knocking out endogenous Rap2b in HCT116 cells using CRISPR-CAS9 technology and the sequencing and identification results. The experimental results showed that Rap2b KO cells were successfully constructed.

[0087] HCT116 or HCT116 Rap2b KO cells were subjected to cell immunofluorescence (IF) and cell membrane protein extraction experiments.

[0088] 2. Cell Immunofluorescence (IF)

[0089] Cell culture plates were used for cell passage in 12-well plates. Cell slides were placed in the wells. 0.015 mg / ml PDL (D-type polylactic acid) was used for coating 1 hour before passage to promote cell adhesion. HCT116 cells were observed to adhere well to the wall under an optical microscope, mainly in the form of single cells. TM 3000 indicates transfection with corresponding plasmid. The following two groups of experiments were mainly carried out

[0090] 1) HCT116 cells were transfected with plasmids Flag-Rap2b, Flag-Rap2b-C176S, Flag-Rap2b-C177S and Flag-Rap2b-C176S / C177S to observe the subcellular localization of Flag-Rap2b, Flag-Rap2b-C176S, Flag-Rap2b-C177S and Flag-Rap2b-C176S / C177S;

[0091] 2) The plasmids Flag-Rap2b / HA (two plasmids co-transfected) and Flag-Rap2b / ABHD17a-HA (two plasmids co-transfected) were transfected into HCT116 Rap2b KO cells respectively to observe the regulatory effect of ABHD17a overexpression on the subcellular localization of Flag-Rap2b.

[0092] 24 hours after cell transfection, cells were fixed with 4% paraformaldehyde and placed at room temperature for 15 minutes. 0.1% Triton X-100 was used to increase cell permeability and placed on ice for 3 minutes. Cells were blocked with 3% BSA (Bovine Serum Albumin) and placed at room temperature for 1 hour. The following primary antibody-labeled proteins were mainly used, including Flag (F7425, Sigma, 1:5000), HA (10028-MM10, SinoBiological, 1:200), Na / KATPase (ab76020, Abcam, 1:500), and incubated overnight at 4°C. After rinsing with PBS, the following secondary antibodies were used for fluorescent staining, including Anti-Rabbit IgGAlexaFluor 594 (A-11012, ThermoFisher, 1:1000) and Anti-Mouse IgGAlexaFluor 594 (A-11029, Thermo Fisher, 1:1000), and placed at room temperature in the dark for 1 hour. After rinsing with PBS, an appropriate amount of Fluoromount-G with DAPI mounting solution was added to the slide, the cell slide was inverted and fixed, and finally the fluorescent images were collected by confocal microscopy, such as Figure 8 , 9 shown.

[0093] 3. Cell membrane protein extraction experiment

[0094] HCT116 or HCT116 Rap2b KO cells were passaged in 10 cm cell culture dishes. When the cell density reached 50% to 60%, the cells were transfected with Lipofectamine TM 3000 indicates transfection with corresponding plasmid. The following two groups of experiments are mainly carried out:

[0095] 1) Observe the plasma membrane distribution of Flag-Rap2b and Flag-Rap2b-C176S / C177S (Flag-2CS) in HCT116 cells;

[0096] 2) HCT116 Rap2b KO cells were used to observe the regulation of ABHD17a-Flag overexpression on the plasma membrane distribution of Flag-Rap2b.

[0097] 24 hours after cell transfection, the cells were rinsed with PBS, and the attached cells were separated by scraper. The cells were collected by centrifugation at 4℃ for 5min, 500rcf. The cells were resuspended with 1ml HME buffer (10mM HEPES, 1mMMgCl2, 1mM EDTA, PH7.4, 1×PI) and lysed by repeated freeze-thaw method for a total of 6 times. The cell lysate was treated with ultrasound, and 150μl was taken as the "Total" group for protein comparison between groups. The remaining samples were centrifuged at 4℃ for 6min, 600rcf, and the supernatant was collected. The precipitate was the nuclear component. The supernatant was centrifuged at 4℃ for 30min, 20000rcf, the supernatant was the cytoplasmic component, and the precipitate was the membrane component. The precipitate was resuspended with 200μl HME, centrifuged at 4℃ for 20min, 10000rcf, and the supernatant was collected. The precipitate was the organelle membrane component. The supernatant was centrifuged at 4℃ for 20min, 20000rcf, and the precipitate was the cell membrane component. 60 μl of lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA) was added to each of the cell nucleus, organelle membrane and cell membrane components to dissolve the precipitate. After the protein concentration of each experimental group was detected by BCA method, the samples were prepared and analyzed by WB. Figure 8 , 9 shown.

[0098] Figure 8 To observe the subcellular localization of Rap2b before and after the palmitoylation modification site mutation through IF and cell membrane protein extraction experiments. Figure 7 C in the middle represents cytoplasm, and PM represents cell membrane. The results showed that before the mutation, Rap2b was mainly distributed in the cell membrane, but after the mutation inhibited the palmitoylation modification of Rap2b, the protein distribution in the cytoplasm increased and the distribution in the cell membrane decreased, suggesting that palmitoylation modification promotes the cell membrane localization of Rap2b.

[0099] Fig. 9 To observe the effect of ABHD17a-Flag overexpression on the plasma membrane distribution of Flag-Rap2b in Rap2b KO cells. The results showed that ABHD17a overexpression reduced the plasma membrane localization of Rap2b.

[0100] 4. Cell scratch assay

[0101] HCT 116Rap2b KO cells were passaged in 10 cm cell culture dishes. When the cell density reached 50% to 60%, the cells were transfected with Lipofectamine TM 3000 indicates transfection with corresponding plasmid. The following two groups of experiments are mainly carried out:

[0102] 1) Observe the effects of Control (Flag), Flag-Rap2b and Flag-Rap2b-C176S / C177S on cell migration;

[0103] 2) Observe the effect of ABHD17a overexpression on Flag-Rap2b-regulated cell invasion.

[0104] 24 h after cell transfection, cells were passaged using Ibidi pre-set wound healing 2-well plug-in culture dishes, with 1.0 × 10 cells seeded per well. 5 100ul / mL, inoculation volume. After the cell density in the well reaches 90% to 100%, remove the plug. After rinsing with PBS, add DMEM / high glucose medium containing 0.5% FBS. According to the ability of cell migration, collect images every 24h until the distance of the scratch is significantly shortened or even closed. The results are shown in Figures 10-11 shown.

[0105] Fig.10 The cell scratch experiment was used to observe the effect of palmitoylation modification site mutation on Rap2b migration ability in Rap2b KO cells.

[0106] Fig.11 A cell scratch assay was used to observe the effect of Rap2b on cell migration ability in Rap2b KO cells under the condition of ABHD17a overexpression intervention.

[0107] Fig.10 , 11 The results showed that Rap2b palmitoylation modification promoted the migration of HCT116 cells, but palmitoylation site mutation or ABHD17a overexpression inhibited this migration ability.

[0108] 5. Transwell and Matrigel experiments

[0109] Transwell and Matrigel experiments use Transwell cell culture chambers with polycarbonate filters to detect the ability of cells to migrate through porous filters. Matrigel experiments add Matrigel (354234, Corning) to Transwell cell culture chambers to simulate the extracellular matrix environment and detect the ability of cells to invade through coated Matrigel and polycarbonate filters.

[0110] Rap2b KO cells were passaged in 10 cm cell culture dishes. When the cell density reached 50% to 60%, the cells were transfected with Lipofectamine TM 3000 indicates transfection with corresponding plasmid. The following two groups of experiments are mainly carried out:

[0111] 1) Observe the effects of Flag, Flag-Rap2b and Flag-Rap2b-C176S / C177S on cell migration and invasion;

[0112] 2) Observe the effect of ABHD17a overexpression on Flag-Rap2b-regulated cell migration and invasion.

[0113] 24 h after cell transfection, Transwell cell culture chambers (with or without Matrigel) were placed in 24-well cell culture wells, and 1.0×10 cells were seeded in each chamber. 5 , inoculation volume 150μl, use DMEM / high glucose medium containing 0.5% FBS. Add 500μl DMEM / high glucose medium containing 10% FBS to the 24-well cell culture wells. After 24h of cell culture, rinse the bottom of the Transwell chamber with PBS, fix the cells with 100% methanol, and rinse with PBS at room temperature. Stain with 0.1% crystal violet, overnight at room temperature, and rinse with PBS. Use a cotton swab to remove non-migrated cells in the chamber, then collect images using an optical microscope, and count the number of migrated cells that pass through the filter membrane in 5 randomly selected fields of view. The results are shown in Fig.12 and Fig.16 shown.

[0114] Fig.12 Transwell and Matrigel experiments were used to observe the effect of Rap2b on cell migration and invasion under the intervention of ABHD17a overexpression. The results showed that Rap2b promoted the migration and invasion of HCT116 cells, but this promoting effect disappeared after ABHD17a overexpressed Rap2b palmitoylation modification.

[0115] Fig.16 The Flag, Flag-Rap2b, and Flag-2CS groups showed that Rap2b promoted the migration and invasion of HCT116 Rap2b KO cells, but this promoting effect disappeared in the Flag-2CS group.

[0116] (III) Research on the regulatory mechanism of Rap2b palmitoylation modification

[0117] This group of studies mainly used the PI3K inhibitor Wortmannin and epidermal growth factor (EGF) to observe the regulatory effect of Rap2b on the EGF / PI3K signaling pathway and the activation of its downstream effector protein AKT / GSK 3β.

[0118] 1. Drug intervention experiment

[0119] Wortmannin (HY-10197, MCE) intervention: HCT116 cells transformed with the corresponding plasmid (Flag-Rap2b) were serum starved for 4 hours, and then treated with 1 μM Wortmannin at 37°C for 60 minutes. DMSO (D2650, Sigma) was used as the control group. The changes in Rap2b palmitoylation before and after Wortmanning were compared by Acyl-RAC assay.

[0120] EGF (HY-P7109, MCE) intervention: HCT116 cells transformed with the corresponding plasmid (Flag-Rap2b) were serum starved for 4 hours, and then treated with 100 ng / ml EGF at 37°C for 5 minutes, with ddH2O as the control group. The changes in Rap2b palmitoylation before and after EGF treatment were compared by Acyl-RAC assay, and the changes in AKT / GSK 3β phosphorylation were observed by WB.

[0121] At the same time, the above two intervention experiments were carried out according to the experiment of extracting cell membrane proteins in part (II). The results are as follows Fig.13 , 14 shown.

[0122] Fig.13 Acyl-RAC experiments were performed to observe the changes in Rap2b palmitoylation in HCT116 cells under the intervention of EGF and Wortmannin. The experimental results showed that the palmitoylation level of Rap2b increased significantly under the intervention of EGF, while the palmitoylation level of Rap2b decreased significantly under the intervention of Wortmannin, suggesting that Rap2b may regulate the migration and invasion of HCT116 cells through the EGF / PI3K signaling pathway.

[0123] Fig.14 In order to observe the subcellular distribution of Rap2b in HCT116 cells under the condition of Wortmannin intervention by extracting cell membrane proteins, the experimental results showed that Rap2b was mainly distributed on the cell membrane, but after Wortmannin intervention, the protein distribution in the cytoplasm increased and the distribution in the cell membrane decreased, suggesting that Wortmannin inhibits the cell membrane localization of Rap2b.

[0124] At the same time, HCT116 Rap2b KO cells were treated with Wortmannin and EGF, and cell scratch, Transwell and Matrigel experiments were performed. Figures 15-16 shown.

[0125] Fig.15 In order to observe the regulatory role of Rap2b on cell migration under the condition of Wortmannin intervention through cell scratch experiment.

[0126] Fig.16 Transwell and Matrigel experiments were used to observe the regulatory role of Rap2b on cell migration and invasion under Wortmannin intervention conditions.

[0127] Fig.15 , 16 The results showed that Rap2b promoted the migration and invasion of HCT116 Rap2b KO cells, but this promoting effect disappeared after Wortmannin intervention, suggesting that Wortmannin regulates Rap2b-mediated tumor cell migration and invasion.

[0128] Fig.17 To observe the changes of phosphorylation modification of AKT / GSK 3β, a downstream effector protein of PI3K signaling pathway in HCT116 cells under EGF intervention conditions through WB experiment. The experimental results showed that Rap2b promoted the phosphorylation modification of AKT / GSK 3β protein dependent on EGF, but this promotion effect disappeared after the palmitoylation modification site of Rap2b was mutated, suggesting that palmitoylation modification of Rap2b regulates the activation of AKT / GSK 3β.

[0129] Example 3

[0130] The above examples dynamically regulate the palmitoylation modification level of Rap2b through palmitoylation modification site mutation, ABHD17a overexpression, and Wortmannin / EGF drug intervention, and clarify that Rap2b palmitoylation modification regulates the migration and invasion of HCT116 and HCT8 cells through the EGF / PI3K and its downstream effector protein AKT / GSK 3β signaling pathway.

[0131] Next, this example uses the amino acid sites (176, 177) of Rap2b as therapeutic targets for colon cancer, and designs small molecule compounds targeting the palmitoylation modification sites of Rap2b.

[0132] (I) Design and preparation of PTG-101

[0133] 1.PTG-101 Design Strategy

[0134] To block the cysteine ​​at positions 176 and 177 of Rap2b, we first looked for naturally derived sequences targeting the NH-GCCS-CO motif. The NH-GCCS-CO motif also exists in some other proteins, but according to the co-crystal structures (PDBID: 2MD6, 4E6K and 6E6S), the motif is usually in a random coil, which greatly limits the design and screening of small molecule compounds with specific recognition. Considering the structural similarity between cysteine ​​and serine, we focused on the NH-EGSSSA-CO motif. In the crystal structure of isoglucanase (PDBID: 1X0C), the motif NH-EGSSSA-CO forms a β-folded structure with the motif NH–ESFEPLSINTTE-CO. However, a part of this motif, NH-PLSINT-CO, forms a small random coil, but it does not seem to affect the binding of small molecule compounds. Therefore, we simplified the motif to H2N-ESFEXTE-COOH and further introduced β-alanine as a linker into the motif to obtain H2N-ESFEβATE-COOH, which was named PTG-101.

[0135] 2. Molecular dynamics simulation of docking between PTG-101 and isoglucanase NH-EGSSSA-CO motif

[0136] Molecular dynamics simulation of the H2N-ESFEβATE-COOH conformation revealed that the former was similar to the NH–ESFEPLSINTTE-CO conformation, and that H2N-ESFEβATE-COOH mainly bound to the NH-EGSSSA-CO motif of isoglucanase through hydrogen bonds.

[0137] Fig.18 Design and docking prediction of PTG-101. (A) Molecular dynamics simulation of H2N-ESFEβATE-COOH (PTG-101, green) conformation, similar to NH-ESFEPLSINTTE-CO (blue). (B) Molecular dynamics simulation predicted docking mode of PTG-101 (green) with NH-EGSSSA-CO motif (amino acids 469-474) in the crystal structure of isoglucanase. Hydrogen bonds are indicated by blue dashed lines.

[0138] Through molecular dynamics simulation, the conformation of H2N-ESFEβATE-COOH was first observed, which was similar to the NH–ESFEPLSINTTE-CO motif (A). Secondly, the interaction between H2N-ESFEβATE-COOH and the NH-EGSSSA-CO motif of isoglucanase was observed, and the binding of the two was mainly completed through hydrogen bonds (B).

[0139] (II) Conducting relevant tests using PTG-101 to verify the effect of this embodiment

[0140] 1. Preparation of PTG-101 storage solution:

[0141] Open the biosafety cabinet, disinfect with 75% alcohol, dissolve 20 mg of PTG-101 in 500 μl of DMSO, aliquot, and store at -80°C.

[0142] 2. Effect of PTG-101 on Rap2b palmitoylation

[0143] After PTG-101 was synthesized, the following cell experiments were performed to first observe the regulatory effect of this small molecule on the palmitoylation modification level of Rap2b, the subcellular distribution of Rap2b regulated by palmitoylation modification, and the promoting effect of Rap2b on the migration and invasion of HCT116 cells.

[0144] 1) Observe the inhibitory effect of PTG-101 on Rap2b palmitoylation modification. HCT116 cells were passaged in 10 cm cell culture dishes. After the cell density reached 70% to 80%, 10 nM, 100 nM, 1 μM, 10 μM and 50 μM PTG-101 were added to the culture medium, and the changes in the palmitoylation modification level of Rap2b were observed by Acyl-RAC experiment.

[0145] 2) The effect of 50 μM PTG-101 on the subcellular distribution of Rap2b was observed by IF. HCT 116 cells were subcultured in 12-well cell culture plates, with cell slides placed in the wells and PDL coated. HCT116 cells were well adhered to the wall under an optical microscope, mainly single cells, and Lipofectamine TM 3000 cells were transfected with Flag-Rap2b for 24 h, and 50 μM PTG-101 was added to the culture medium. IF was used to observe the changes in the subcellular distribution of Rap2b 24 h later.

[0146] 3) Observe the effect of 50 μM PTG-101 on the subcellular distribution of Rap2b by cell membrane protein extraction. HCT 116 cells were passaged in 10 cm cell culture dishes. When the cell density reached 70% to 80%, 50 μM PTG-101 was added to the culture medium. After 24 hours, the changes in the distribution of Rap2b in the cell membrane and cytoplasmic components were observed by cell membrane protein extraction experiments.

[0147] 4) The effect of 50 μM PTG-101 on Rap2b-regulated cell migration was observed by scratch test. HCT116 cells were passaged using Ibidi pre-set wound healing 2-well plug culture dishes. When the cell density in the well reached 90% to 100%, the plug was removed and DMEM / high glucose medium containing 0.5% FBS and 50 μM PTG-101 was added. Images were collected every 24 hours until obvious differences between the groups appeared.

[0148] 5) The effect of 50 μM PTG-101 on Rap2b-regulated cell invasion was observed by Transwell and Matrigel experiments. HCT116 cells were passaged using Transwell cell culture chambers (with or without Matrigel) and placed in 24-well cell culture wells. DMEM / high glucose medium containing 0.5% FBS was added to the chamber, and 500 μl of DMEM / high glucose medium containing 10% FBS and 50 μM PTG-101 was added to the chamber. After 24 hours of culture, the cells at the bottom of the chamber were fixed with 100% methanol, stained with 0.1% crystal violet, and images were collected by optical microscopy to count the number of migrated cells that passed through the filter membrane.

[0149] Fig.19 Acyl-RAC experiments were performed to observe the changes in Rap2b palmitoylation under the intervention of different doses of PTG-101. The experimental results showed that under the intervention of PTG-101, the level of Rap2b palmitoylation showed a downward trend, showing a dose-dependent positive correlation, suggesting that PTG-101 can inhibit Rap2b palmitoylation, and confirming the intervention dose of 50μM in subsequent experiments.

[0150] Fig. 20 The subcellular distribution of Rap2b under PTG-101 intervention was observed by IF and cell membrane protein extraction experiments. The experimental results showed that Rap2b protein was mainly distributed on the cell membrane, but after PTG-101 intervention, the protein distribution in the cytoplasm increased and the distribution in the cell membrane decreased, suggesting that PTG-101 inhibits the cell membrane localization of Rap2b.

[0151] Fig.21 A cell scratch experiment was used to observe the regulation of Rap2b on cell migration under PTG-101 intervention conditions.

[0152] Fig. 22 Transwell and Matrigel experiments were used to observe the regulation of Rap2b on cell migration and invasion under PTG-101 intervention conditions.

[0153] Fig.21 , 22The results showed that Rap2b promoted the migration and invasion of HCT116 cells, but this promoting effect disappeared after PTG-101 intervention, suggesting that PTG-101 regulates Rap2b-mediated tumor cell migration and invasion.

[0154] 2. Establishment of Rectal Cancer Xenograft Mouse Model

[0155] Construction of Luciferase-GFP-puro (EV or GFP), GFP-Rap2b (Rap2b) and GFP-Rap2b-2M (Rap2b-2CS or GFP-2CS) stably transfected HCT116 Rap2b KO cells: Lentivirus expression vectors can be used for stable gene expression in HCT116 Rap2b KO cells. HCT116 Rap2b KO cells were passaged in 10 cm cell culture dishes. When the cell density reached 20% to 30%, appropriate amounts of lentivirus solution and infection enhancement solution HitransGA (GeneScript) were added. After 36 hours, the transfection results were observed under a fluorescence microscope, and further fluorescence sorting was performed by flow cytometry. After cell amplification, the expression of Rap2b was detected by WB. Reserve.

[0156] Preparation of PTG-101 lipid nanoparticles (LNPs): To prepare PTG-101-LNPs, Cholesterol and PL-100M (20.5 mg) were fully dissolved in chloroform at a ratio of 1:9 (mass ratio) and evaporated under reduced pressure to obtain a lipid film. Then, 1 ml of 5 mM PTG-101 solution (dissolved in 0.9% NaCl) was added and incubated at 20°C for 10 min. The resulting solution was extruded 3 times through a 200 nm polycarbonate membrane, aliquoted, and stored at -20°C.

[0157] Mouse lung metastasis model: 4-6 week-old Balb / c nude mice were inoculated with the above-mentioned Luciferase-GFP-puro, GFP-Rap2b or GFP-Rap2b-2M stably transfected HCT116 cells via tail vein injection using a BD insulin syringe for about 10 7 After inoculation, mice were weighed weekly until they were sacrificed, and the fluorescence signals were observed by in vivo imaging.

[0158] Rap2b / PTG-101 group mice: PTG-101-LNPs were given 10 days after tumor inoculation, and the blood drug concentration was set to twice the cellular drug concentration, i.e. 100 μM. Assuming that the mouse is 20 g, the blood volume is 1.6 ml (about 8% of body weight), and the drug is given by intraperitoneal injection once a day (bioavailability 80%), with 40 μl of PTG-101-LNPs injected each time until sacrifice.

[0159] On the 50th day after inoculation, the mice were killed and lung tissues were obtained. Some of them were paraffin-sectioned and HE-stained to observe the pathological changes of the lungs. Some were subjected to WB detection to observe the changes in the phosphorylation modification level of AKT / GSK 3β protein. Figures 23 to 25 shown.

[0160] The above-mentioned paraffin sectioning procedure has been described in Example 1.

[0161] HE staining: paraffin sections were heated at 60℃ for 2h, and then dewaxed and hydrated in order of xylene (10min) → xylene (10min) → anhydrous ethanol (5min×2 times) → 95% ethanol (5min×2) → 90% ethanol (5min) → 85% ethanol (5min) → 80% ethanol (5min) → ddH2O (5min). Stained with hematoxylin for 5min, rinsed with running water for 5min. 1% hydrochloric acid ethanol for 30sec, washed with ddH2O for 30sec. Stained with 0.5% eosin solution for 1-3min, washed with ddH2O for 30sec. Dehydrated with gradient alcohols of 80% ethanol (2min) → 95% ethanol (2min) → 100% ethanol (2min×2), transparentized with xylene (5min×2), and sealed with neutral gum.

[0162] Fig.23 The regulatory effect of PTG-101 on Rap2b-mediated tumor metastasis in a colon cancer xenograft mouse model. The experimental results showed that Rap2b overexpression promoted colon cancer metastasis, but this promotion effect was significantly reduced under Rap2b palmitoylation modification site mutation or PTG-101 intervention.

[0163] Fig.24 In order to observe the regulation of PTG-101 on the degree of lesions in the colon cancer xenograft mouse model by HE staining of the lungs, changes in body weight and survival, the experimental results showed that Rap2b overexpression led to a significant decrease in the body weight and survival of mice, but the changes in body weight and survival of mice were significantly improved under the intervention of Rap2b palmitoylation modification site mutation or PTG-101.

[0164] Fig.25To observe the regulatory effect of PTG-101 on the AKT / GSK 3β signaling pathway in a colon cancer xenograft mouse model by WB. The experimental results showed that Rap2b overexpression promoted the activation of the AKT / GSK 3β signaling pathway, but this promotion effect was significantly reduced under the mutation of the palmitoylation modification site of Rap2b or the intervention of PTG-101.

[0165] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of Rap2b amino acid site as a target for preparing drugs for treating colorectal cancer, characterized in that: The Rap2b amino acid site is the 176th and / or 177th cysteine ​​on the Rap2b amino acid sequence, and the Rap2b amino acid sequence is shown in SEQ ID NO:

1.

2. The use according to claim 1, characterized in that The drug is prepared for treating colorectal cancer by blocking the post-translational modification of cysteine ​​at position 176 and / or 177 on the amino acid sequence of Rap2b.

3. The use according to claim 2, characterized in that The post-translational modification refers to palmitoylation modification.

4. A motif for blocking post-translational palmitoylation modification of the amino acid site of Rap2b in the use according to any one of claims 1 to 3, characterized in that: The motif is a naturally derived sequence targeting an NH-GCCS-CO motif or a naturally derived sequence targeting an NH-EGSSSA-CO motif.

5. The motif according to claim 4, characterized in that The naturally derived sequence targeting the NH-EGSSSA-CO motif is NH-ESFEPLSINTTE-CO.

6. The motif according to claim 5, characterized in that The NH-EGSSSA-CO motif interacts with the NH-ESFEPLSINTTE-CO motif to form a β-sheet structure.

7. The motif according to claim 5, characterized in that The simplified sequence of the NH-ESFEPLSINTTE-CO motif is H2N-ESFEXTE-COOH, wherein X represents 1 to 6 arbitrary amino acids.

8. The motif according to claim 7, characterized in that The X is β-alanine, and a H2N-ESFEβATE-COOH motif is obtained; the H2N-ESFEβATE-COOH motif simulates the conformation of the NH-ESFEPLSINTTE-CO motif, interacts with the NH-EGSSSA-CO motif through hydrogen bonds, and is used to treat colorectal cancer.

9. Use of the motif according to any one of claims 4 to 8 in the preparation of a drug for treating colorectal cancer.

10. Use of an overexpression reagent of ABHD17a in the preparation of a drug for reducing the palmitoylation modification level of cysteine ​​at position 176 and / or 177 in the amino acid sequence of Rap2b.